Panitumumab

The Application of Transgenic Mice for Therapeutic Antibody Discovery

In 2006, panitumumab, the first fully human antibody generated from transgenic mice, was approved for clinical use by the US Food and Drug Administration (FDA). Since then, a further seven such antibodies have been approved. In this chapter

绝处逢生，靳令经/李华/叶克强等开发双靶点抑制剂，间接靶向EGFR来治疗胶质母细胞瘤

剂主要有阿法替尼、达克替尼等。第一、二代靶向药疗效显著，但副作用也比较大，且多数患者服用 1-2 年出现耐药性。第一代药物耐药后可用第三代靶向药，主要代表药有奥西替尼等，第三代靶向药亦出现耐药性。然而，现有研究表明使用 EGFR 为靶点治疗胶质瘤仍有许多问题。靶向 EGFR 开发的抗体并未能改善患者的生存率。仅有Panitumumab（帕尼单抗）是唯一可以同时中和 EGFRvIII 和 wtEGFR 的抗体，减弱下游 p-S6 信号，具有良好的体外和体内的抗肿瘤活性。如何发现新的可成药靶点，开发

【翻译】Development trends for monoclonal antibody cancer therapeutics

; ImClone/Bristol-Myers Squibb), nimotuzumab (TheraCIM; YM BioSciences) and panitumumab (Vectibix; Amgen). These products inhibit binding of EGF and subsequent activation of the EGF receptor33, 34. The in vivo mechanism of action of trastuzumab